Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Resistance's irresistible need

Industry's anti-infective efforts step up a gear

AntibioticsAntimicrobial resistance. It's not, perhaps, a particularly dynamic topic, but it will be a priority one for 2014, at least as far as the EMA is concerned. 

Finalising its 2014 work programme late last year the European regulator made “tackling the issue of antimicrobial resistance and availability of anti-infective treatment options” one of its focus areas for this year.  

The area has gradually been gaining momentum, especially during the last 12 months, beginning in February when EU efforts to combat the issue saw five major pharma firms partner under the auspices of the Innovative Medicines Initiative's (IMI) New Drugs for Bad Bugs programme.  

As bacterial infections grow increasingly resistant to current treatments, leaving doctors with fewer options, individual companies have made progress on researching new antibiotics.  

Cubist looks to be on track to file its new antibiotic later this year after posting positive phase III data in December and AstraZeneca, despite planning to cut back on its anti-infectives research, forged a new partnership in November with Singapore's main research centre.  

As was noted on PMLiVE recently, the discovery of antibacterial drugs was a transformative moment in human history, but increasing resistance demands a global commitment to develop new drugs. Clearly, when antimicrobial resistance still causes 25,000 deaths each year, the need for pharma successes in this area is irresistible.

Article by
Dominic Tyer

editorial director of PMGroup

14th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics